Rhenman & Partners Asset Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Rhenman & Partners Asset Management’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-30,000	Closed	-$1.29M	–	105
2017 Q2	$1.29M	Sell	30,000 -200,000	-87%	-$7.12M	0.19%	82
2017 Q1	$7.2M	Sell	230,000 -20,000	-8%	-$536K	1.14%	34
2016 Q4	$6.31M	Sell	250,000 -20,000	-7%	-$447K	1.21%	33
2016 Q3	$6.68M	Sell	270,000 -10,000	-4%	-$226K	1.06%	35
2016 Q2	$5.7M	Buy	280,000 +10,000	+4%	+$177K	1.01%	37
2016 Q1	$4.12M	Sell	270,000 -18,000	-6%	-$235K	0.82%	47
2015 Q4	$3.87M	Sell	288,000 -65,328	-18%	-$1.01M	0.59%	60
2015 Q3	$4.96M	Sell	353,328 -63,672	-15%	-$1.18M	0.79%	50
2015 Q2	$7.08M	Sell	417,000 -33,800	-7%	-$481K	0.85%	37
2015 Q1	$5.45M	Buy	450,800 +200,000	+80%	+$1.89M	0.92%	40
2014 Q4	$2.08M	Buy	250,800 +38,800	+18%	+$326K	0.6%	72
2014 Q3	$1.84M	Sell	212,000 -15,000	-7%	-$135K	0.54%	79
2014 Q2	$2.49M	Buy	227,000 +30,463	+15%	+$271K	0.74%	51
2014 Q1	$1.76M	Sell	196,537 -28,463	-13%	-$262K	0.53%	66
2013 Q4	$1.7M	Buy	+225,000	New	+$1.57M	0.66%	66

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

RCAMU

Rothschild & Co Asset Management US Stamford, Connecticut $6.58B AUM 4.5% 1-Year Est. Return

Rhenman & Partners Asset Management's SUPN Position: Q3 2017 in Review

Rhenman & Partners Asset Management sold out of Supernus Pharmaceuticals (SUPN) in Q3 2017, closing a stake of 30,000 shares — an estimated $1.29M sold.

Rhenman & Partners Asset Management first reported a position in SUPN in Q4 2013 and held it in 15 quarters. The position peaked at $7.2M in Q1 2017. 275 funds tracked by Wall St. Rank hold SUPN as of Q3 2017.

Rhenman & Partners Asset Management reported no remaining Supernus Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
Rhenman & Partners Asset Management sold 30,000 Supernus Pharmaceuticals shares in Q3 2017, an estimated $1.29M.
Rhenman & Partners Asset Management first reported a position in Supernus Pharmaceuticals in Q4 2013 and held it in 15 quarters.
Rhenman & Partners Asset Management's Supernus Pharmaceuticals position peaked at $7.2M in Q1 2017.
275 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2017.

Based on Rhenman & Partners Asset Management's 13F filing for Q3 2017, filed 13 Oct 2017.